Preventive Cardiology

Immunization and Cardiovascular Protection: Evidence andFuture Directions

by Prateek Chopra | June 12, 2026 | Cardiology Conferences | ESH 2026 Clinical Rationale: Growing evidence supports a bidirectional relationship between infections and cardiovascular disease (CVD). Respiratory infections can trigger acute cardiovascular events and exacerbate pre-existing conditions, while patients with underlying CVD are at higher risk of severe infectious outcomes. Influenza infection, for example, increases the incidence of acute myocardial […]

Immunization and Cardiovascular Protection: Evidence andFuture Directions Read Post »

Leave a Comment / ESH Day 3 / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiovascular Disease Prevention, Cardiovascular Risk Reduction, COVID-19 Vaccination, Influenza Vaccination, Preventive Cardiology

Integrated Polygenic Scores: Are They Ready for Clinical Practice?

by Prateek Chopra | June 7, 2026 | Cardiology Conferences | ESH 2026 Precision Cardiovascular Prevention: Integrated polygenic risk scores (PRS) enhance risk stratification beyond traditional risk factors. PRS predicts coronary artery disease (CAD) 2–4 times more strongly than conventional risk factors and identifies high-risk individuals not captured by family history or standard clinical assessments. High-Risk Populations: Evidence from Clinical Trials:

Integrated Polygenic Scores: Are They Ready for Clinical Practice? Read Post »

Leave a Comment / ESH Day 2 / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiovascular Risk Assessment, Coronary Artery Disease (CAD), Polygenic Risk Score (PRS), Precision Cardiovascular Medicine, Preventive Cardiology

Treatment Algorithms for Hypertensive Patients with Hyperlipidaemia and Diabetes, Including Management Beyond Triple Combination Therapy

by Prateek Chopra | June 7, 2026 | Cardiology Conferences | ESH 2026 Optimizing Cardiovascular Risk: Prof. Andrzej highlighted standardized CVD mortality rates across regions, emphasizing major risk factors including BMI, systolic blood pressure, non-HDL cholesterol, diabetes, and smoking. Expanded clinical conditions such as resistant hypertension, sleep disorders, chronic inflammation, NAFLD, and migraine, as well as emerging risk factors like sedentary

Treatment Algorithms for Hypertensive Patients with Hyperlipidaemia and Diabetes, Including Management Beyond Triple Combination Therapy Read Post »

Leave a Comment / ESH Day 2 / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiovascular Risk Assessment, Hypertension Management, Preventive Cardiology, SGLT2 Inhibitors, Single-Pill Combination Therapy